Xencor Inc XNCR:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:00 PM EDT
23.77UNCH (UNCH)
Volume
15,268
Close
23.77quote price arrow up+0.02 (+0.08%)
Volume
546,822
52 week range
16.49 - 28.96
Loading...
  • Open23.63
  • Day High24.05
  • Day Low23.28
  • Prev Close23.75
  • 52 Week High28.96
  • 52 Week High Date05/23/23
  • 52 Week Low16.49
  • 52 Week Low Date11/09/23

Key Stats

  • Market Cap1.466B
  • Shares Out61.66M
  • 10 Day Average Volume0.66M
  • Dividend-
  • Dividend Yield-
  • Beta0.81
  • YTD % Change11.96

KEY STATS

  • Open23.63
  • Day High24.05
  • Day Low23.28
  • Prev Close23.75
  • 52 Week High28.96
  • 52 Week High Date05/23/23
  • 52 Week Low16.49
  • 52 Week Low Date11/09/23
  • Market Cap1.466B
  • Shares Out61.66M
  • 10 Day Average Volume0.66M
  • Dividend-
  • Dividend Yield-
  • Beta0.81
  • YTD % Change11.96

RATIOS/PROFITABILITY

  • EPS (TTM)-2.19
  • P/E (TTM)-10.84
  • Fwd P/E (NTM)-7.06
  • EBITDA (TTM)-124.341M
  • ROE (TTM)-20.58%
  • Revenue (TTM)162.181M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-82.74%
  • Debt To Equity (MRQ)3.34%

EVENTS

  • Earnings Date08/01/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Xencor Inc

 

Profile

MORE
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly owned development candidates include Vudalimab...
Bassil Dahiyat Ph.D.
President, Chief Executive Officer, Founder and Director
Bart Cornelissen
Chief Financial Officer, Senior Vice President
John Desjarlais Ph.D.
Executive Vice President - Research, Chief Scientific Officer
Nancy Valente M.D.
Executive Vice President, Chief Development Officer
Address
465 N. HALSTEAD ST., SUITE 200
Pasadena, CA
91107
United States

Top Peers

SYMBOLLASTCHG%CHG
LGND
Ligand Pharmaceuticals Inc
87.00+0.37+0.43%
RCUS
Arcus Biosciences Inc
17.24+0.46+2.74%
DNA
Ginkgo Bioworks
0.7313-0.0348-4.5425%
DVAX
Dynavax Technologies Corp
11.46+0.07+0.61%
ARDX
Ardelyx Inc
7.72-0.21-2.65%